Providence Therapeutics is Canada’s leading mRNA vaccine company, with operations in Calgary, Alberta, and Toronto, Ontario. Providence Therapeutics has focused its resources on constructing a world-class COVID-19 vaccine ever since a worldwide COVID-19 vaccine need was identified.
On February 11, 2021, Providence Therapeutics announced that Manitoba’s Government bought two million doses of its proprietary mRNA (messenger RNA) COVID-19 vaccine PTX-COVID19-B.
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
This year, Providence Therapeutics’ messenger RNA (mRNA) vaccine became the first made to order vaccine to begin Phase 1 trials in humans. Regulatory approval is still pending for Phase 2 trials, which are expected to start in May 2021.
Vaccines for COVID-19 is now on course to be manufactured and delivered in Canada in 2021. Eventually, we anticipate working with other provinces and the federal government to manufacture vaccines for more Canadians across the country, Brad Sorenson, CEO of Providence Therapeutics, said.
The mRNA-vaccine PTX-COVID19-B completed the stage of high dose safety and is the first wholly Canadian candidate for COVID vaccines.
Securing a supply of made-in-Canada vaccines will provide more Canadians access to COVID-19 sooner. The Government of Manitoba is delighted to work with Providence Therapeutics and its Manitoba partners to produce the vaccines here at home. This agreement gives us a chance to build a national vaccination program to help protect all Canadians. Other provinces and the federal government are urged to join us in making this national program, said Premier Brian Pallister.
Providence Therapeutics has partnered with Northern RNA, an Alberta-based vaccine manufacturing firm, to provide raw materials.
Providence looks forward to working with all its partners in delivering these critical vaccines as soon as possible to Canadians.